Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC® in Israel. GelrinC is Regentis' proprietary implant for repairing damaged knee cartilage and has received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States.
Under the agreement, AMI will leverage its established relationships with orthopedic surgeons, hospitals, and clinics to support the product's commercial introduction. The deal includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in 2027. The companies will also collaborate to establish reimbursement coverage for GelrinC with Israel's leading health maintenance organizations and promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement coverage is established, patients may be able to access the implant through private health insurance.
The agreement supports Regentis' broader commercialization efforts in Europe and Israel as the company continues advancing its pivotal Phase 3 clinical program in the United States. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The company aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
For investors, the distribution deal provides a clear path to revenue in a new market and validates the company's regulatory and commercial strategy. The inclusion of minimum purchase requirements offers some visibility into future sales, while the collaboration on reimbursement with health maintenance organizations is critical for broader adoption. The news comes as Regentis continues to develop its U.S. pivotal trial, which, if successful, could open a significantly larger market opportunity.
The full press release can be viewed at https://ibn.fm/t1dw4. For more information about Regentis Biomaterials, visit its relationship page. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid investor awareness and marketing engagement. MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries, as well as article and editorial syndication to 5,000+ outlets. For more information, please visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
